Elimination of canrenone in congestive heart failure and chronic liver disease

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Clinical Pharmacology
• Cardiology and Hepatology

Background:

• Spironolactone is a medication used for heart failure and liver disease.
• Canrenone is the primary active metabolite of spironolactone.
• Understanding canrenone's elimination half-life is crucial for assessing drug efficacy and safety in specific patient populations.

Purpose of the Study:

• To determine the elimination half-life (T1/2) of canrenone in patients with chronic liver disease and congestive heart failure.
• To compare canrenone's T1/2 in these patient groups with that of healthy subjects.
• To investigate potential plasma accumulation of canrenone in patients with prolonged T1/2.

Main Methods:

• Measured the elimination half-life of canrenone in 5 patients with chronic liver disease and 7 patients with congestive heart failure.
• Compared the determined half-lives with previously reported values in normal subjects and data from the current study's normal subjects.

Main Results:

• Canrenone's elimination half-life was significantly prolonged in patients: 59 hours (range 32-105 h) in liver disease and 37 hours (range 19-48 h) in heart failure.
• In comparison, the T1/2 in normal subjects was 13.5-24 h (previous reports) and 20.5 h (current study).
• No evidence of increased canrenone accumulation in plasma was observed in patients with a prolonged T1/2.

Conclusions:

• Patients with chronic liver disease and congestive heart failure exhibit significantly longer elimination half-lives for canrenone.
• Despite prolonged half-lives, canrenone does not appear to accumulate in the plasma of these patient groups.
• These findings have implications for spironolactone dosing and monitoring in patients with compromised liver or cardiac function.